Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope

Posted: Published on January 15th, 2015

This post was added by Dr P. Richardson

January 15, 2015 1:50 pm by Meghana Keshavan | 0 Comments MedCity News

Bluebird Bios work has beenatthe epicenter of gene therapy, working on a litany of fields that intersect with the work of the industrys top firms. This slide from its J.P. Morgan presentation this week illustrates that quite nicely:

The companys stock has just killed it in the past year from $BLUE trading around $17 per share a year ago to hitting highs above $100 this year.

Biopharma Dive wrote of the #JPM15 presentation:

Its one of the hottest biotechsin the world, and its planning on presenting major clinical data by the end of the year. bluebird bio CEONick Leschly told JPM15 attendees that the company will unveil data for its ambitious sickle cell gene therapy platform LentiGlobinin 2015.

Worth watching, if you havent, is CEO Nick Leschlys TEDxBoston talk from a couple years ago.

Get our daily newsletter or follow us.

Please enter your email below:

Read more:
Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope

Related Posts
This entry was posted in Gene Therapy. Bookmark the permalink.

Comments are closed.